Loading
A phase 2 trial of Ivonescimab, AK117, CAPOX in colorectal cancer, run by Akeso, active and no longer recruiting.
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer is a phase 2 interventional study registered as NCT05382442 by Akeso, with 254 participants planned, started 2022-06-27 and due to reach its primary completion in 2026-05-15. Interventions recorded: AK112, AK117, Oxaliplatin, Capecitabine, Irinotecan. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares Akeso, Ivonescimab, FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin).
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Colorectal cancer.